BackgroundInfiltrative basal cell carcinoma (BCC) has a higher risk for post-surgical recurrence as compared to the most common low-aggressive superficial and nodular BCC. Independent diagnostic criteria for infiltrative BCC diagnosis have not been still defined. Improving the pre-surgical recognition of infiltrative BCC might significantly reduce the risk of incomplete excision and recurrence.ObjectiveThe aim of this study is to define clinical and dermoscopic criteria that can differentiate infiltrative BCC from the most common low-aggressive superficial and nodular BCC.MethodsClinical and dermoscopic images of infiltrative, superficial, and nodular BCC were retrospectively retrieved from our database and jointly evaluated by two experienced dermoscopists, blinded for the histologic subtype. Pairwise comparisons between the three histologic subtypes were performed and multivariable logistic regression models were constructed in order to define clinical and dermoscopic factors independently associated with each subtype. To validate our findings, two experienced dermoscopists not previously involved in the study were asked to evaluate clinical and dermoscopic images from an external dataset, guessing the proper BCC subtype between infiltrative, nodular and superficial, before and after being provided with the study results.ResultA total of 481 histopathologically proven BCCs (51.4% nodular, 33.9% superficial, and 14.8% infiltrative) were included. We found that infiltrative BCC mostly appeared on the head and neck as an amelanotic hypopigmented plaque or papule, displaying ulceration on dermoscopic examination, along with arborizing and fine superficial telangiectasia. Shiny white structures were also frequently observed. Multivariate regression analysis allowed us to define a clinical-dermoscopic profile of infiltrative BCC.ConclusionsWe defined the clinical-dermoscopic profile of infiltrative BCC, allowing to differentiate this variant from superficial and nodular BCC. This will improve pre-surgical recognition of infiltrative forms, reducing the risk for post-surgical recurrence.
Objectives --- Microdosimetry is proving to be a reliable and powerful tool to be applied in different fields such as radiobiology, radiation protection and hadron therapy. However, accepted standard protocols and codes of practice are still missing. With this regard, a systematic and methodical uncertainty analysis is fundamental to build an accredited uncertainty budget of practical use. This work studied the contribution of counting statistics (i.e. number of events collected) to the final frequency-mean and dose-mean lineal energy uncertainties, aiming at providing guidelines for good experimental and simulation practice. The practical limitation of current technologies and the non-negligible probability of nuclear reactions require careful considerations and non-linear approaches. Approach --- Microdosimetric data were obtained by means of the particle tracking Monte Carlo code Geant4. The uncertainty analysis was carried out relying on a Monte Carlo based numerical analysis, as suggested by the BIPM’s “Guide to the expression of uncertainty in measurement”. Final uncertainties were systematically investigated for proton, helium and carbon ions at an increasing number of detected events, for a range of different clinical-relevant beam energies. Main results --- Rare events generated by nuclear interactions in the detector sensitive volume were found to massively degrade microdosimetric uncertainties unless a very high statistics is collected. The study showed an increasing impact of such events for increasing beam energy and lighter ions. For instance, in the entrance region of a 250MeV proton beam, about 5e7 events need to be collected to obtain a dose-mean lineal energy uncertainty below 10%. Significance --- The results of this study help define the necessary conditions to achieve appropriate statistics in computational microdosimetry, pointing out the importance of properly taking into account nuclear interaction events. Their impact on microdosimetric quantities and on their uncertainty is significant and cannot be overlooked, particularly when characterising clinical beams and radiobiological response. This work prepared the ground for deeper investigations involving dedicated experiments and for the development of a method to properly evaluate the counting statistics uncertainty contribution in the uncertainty budget, whose accuracy is fundamental for the clinical transition of microdosimetry.
The interest in hadron therapy is growing fast thanks to the latest technological advances in accelerators and delivery technologies, to the development of more and more efficient and comprehensive treatment planning tools, and due to its increasing clinical adoption proving its efficacy. A precise and reliable beam quality assessment and an accurate and effective inclusion of the biological effectiveness of different radiation qualities are fundamental to exploit at best its advantages with respect to conventional radiotherapy. Currently, in clinical practice, the quality assurance (QA) is carried out by means of conventional dosimetry, while the biological effectiveness of the radiation is taken into account considering the Relative Biological Effectiveness (RBE). The RBE is considered a constant value for protons and it is estimated as a function of the absorbed dose in case of carbon ions. In this framework, microdosimetry could bring a significant improvement to both QA and RBE estimation. By measuring the energy deposited by the radiation into cellular or sub-cellular volumes, microdosimetry could provide a unique characterisation of the beam quality on one hand, and a direct link to radiobiology on the other. Different detectors have been developed for microdosimetry, from the more conventional tissue equivalent proportional counter (TEPC), silicon-based and diamond-based solid-state detectors, to ΔE-E telescope detectors, gas electrons multiplier (GEM), hybrid microdosimeters and a micro-bolometer based on Superconducting QUantum Interference Device (SQUID) technology. However, because of their different advantages and drawbacks, a standard device and an accredited experimental methodology have not been unequivocally identified yet. The establishment of accepted microdosimetry standard protocols and code of practice is needed before the technique could be employed in clinical practice. Hoping to help creating a solid ground on which future research, development and collaborations could be planned and inspired, a comprehensive state of the art of the detector technologies developed for microdosimetry is presented in this review, discussing their use in clinical hadron therapy conditions and considering their advantages and drawbacks.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.